Jiangsu Senxuan Pharmaceutical920946.BJValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Jiangsu Senxuan Pharmaceutical (920946.BJ) trades at a P/E of 28.20x, P/B of 3.37x, P/S of 6.76x, and a dividend yield of 1.57%.
Longitudinal percentile comparison: P/E sits at the 59th percentile over the trailing 10Y window (vs. 38th percentile over 3Y); P/B sits at the 52nd percentile over the trailing 10Y window (vs. 48th percentile over 3Y); P/S sits at the 64th percentile over the trailing 10Y window (vs. 42nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 46th percentile within its industry and the 39th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.57%, ranking at the 38th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 7.7 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jiangsu Senxuan Pharmaceutical operates in the — sector. Data refreshes weekly and is for reference only, not investment advice.
Want the full picture on whether Jiangsu Senxuan Pharmaceutical (920946.BJ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 28.20 | ||||||
| P/B (MRQ) | 3.37 | ||||||
| P/S (TTM) | 6.76 | ||||||
| Dividend Yield | 1.57% | ||||||
| Buyback + Div Yield | 1.57% |